Edwards Lifesciences Co. (NYSE:EW) Stock Position Decreased by Advisor OS LLC

Advisor OS LLC cut its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 1.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,102 shares of the medical research company’s stock after selling 216 shares during the period. Advisor OS LLC’s holdings in Edwards Lifesciences were worth $1,395,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Crewe Advisors LLC bought a new position in shares of Edwards Lifesciences in the 1st quarter valued at approximately $28,000. First Community Trust NA bought a new position in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $29,000. Riverview Trust Co bought a new position in shares of Edwards Lifesciences in the 1st quarter valued at approximately $34,000. DSM Capital Partners LLC bought a new position in shares of Edwards Lifesciences in the 4th quarter valued at approximately $28,000. Finally, Webster Bank N. A. bought a new position in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $39,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $93.29, for a total value of $466,450.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at $4,378,659.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $93.29, for a total transaction of $466,450.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at $4,378,659.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Daveen Chopra sold 1,250 shares of the stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the transaction, the vice president now directly owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 16,250 shares of company stock valued at $1,321,988. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Up 1.2 %

EW stock opened at $66.81 on Friday. The company has a market cap of $40.26 billion, a P/E ratio of 28.80, a PEG ratio of 2.92 and a beta of 1.11. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08. The business has a fifty day moving average of $74.75 and a 200-day moving average of $84.17.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The firm had revenue of $1.63 billion during the quarter, compared to analysts’ expectations of $1.65 billion. During the same period in the previous year, the firm earned $0.66 earnings per share. The company’s revenue was up 6.7% on a year-over-year basis. As a group, equities research analysts expect that Edwards Lifesciences Co. will post 2.7 EPS for the current year.

Wall Street Analysts Forecast Growth

EW has been the topic of a number of recent analyst reports. Daiwa Capital Markets raised Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a research note on Wednesday, July 31st. Baird R W downgraded Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 25th. Daiwa America raised Edwards Lifesciences to a “strong-buy” rating in a research report on Wednesday, July 31st. TD Cowen downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating and dropped their price target for the stock from $100.00 to $70.00 in a research report on Thursday, July 25th. Finally, Canaccord Genuity Group dropped their price target on Edwards Lifesciences from $85.00 to $77.00 and set a “hold” rating on the stock in a research report on Thursday, July 25th. Fourteen analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average price target of $82.10.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.